Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation

• Published in: Frontiers in immunology Vol. 10; p. 2516
• Main Authors: Chang, Ying-Jun, Zhao, Xiang-Yu, Huang, Xiao-Jun
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 01.11.2019
• Subjects: granulocyte colony-stimulating factor; haploidentical stem cell transplantation; Immunology; poor graft function; relapse; virus infections; granulocyte colony-stimulating factor; relapse; haploidentical stem cell transplantation; poor graft function; virus infections
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2019.02516

Granulocyte colony-stimulating factor (G-CSF), a growth factor for neutrophils, has been successfully used for stem cell mobilization and T cell immune tolerance induction. The establishment of G-CSF-primed unmanipulated haploidentical blood and marrow transplantation (The Beijing Protocol) has achieved outcomes for the treatment of acute leukemia, myelodysplastic syndrome, and severe aplastic anemia with haploidentical allografts comparable to those of human leukocyte antigen (HLA)-matched sibling donor transplantation. Currently, G-CSF-mobilized bone marrow and/or peripheral blood stem cell sources have been widely used in unmanipulated haploidentical transplant settings. In this review, we summarize the roles of G-CSF in inducing T cell immune tolerance. We discuss the recent advances in the Beijing Protocol, mainly focusing on strategies that have been used to improve transplant outcomes in cases of poor graft function, virus infections, and relapse. The application of G-CSF-primed allografts in other haploidentical modalities is also discussed.